Background: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular
disease independently of classic risk factors. Proprotein Convertase Subtilisin/Kexin type 9 …

Background In parallel to the increasing prevalence of metabolic syndrome, the prevalence
of hepatic steatosis has also increased dramatically worldwide. Hepatic steatosis is a major …

Background and aims Some studies suggested that proprotein convertase subtilisin kexin
type 9 (PCSK9) is linked to liver steatosis severity and non-alcoholic steatohepatitis (NASH) …

Background High fat diet (HFD) increases the likelihood of dyslipidemia, which can be a
serious risk factor for atherosclerosis, diabetes or hepatosteatosis. Although changes in …

Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease
(NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD. Objective: The aim …

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in
Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase …

Abstract Background and Aims The proprotein convertase subtilisin/kexin type 9 (PCSK9)
plays a key role in cholesterol homeostasis, and its inhibition represents an effective therapy …

Introduction There are inconsistent findings regarding the effect of lipid-lowering agents on
nonalcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 …

Dyslipidemia and altered iron metabolism are typical features of nonalcoholic fatty liver
disease (NAFLD). Proprotein convertase subtilisin/kexin type 7 (PCSK7) gene variation has …

Background and aims Nonalcoholic fatty liver disease (NAFLD) may be crucial in subjects
with familial hypercholesterolemia (FH). We aimed to evaluate the effect of the inhibitors of …